(Q34583603)

English

CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor (English)

1 reference

Europe PubMed Central

3 August 2017

Helicobacter pylori

1 reference

based on heuristic

inferred from title

pharmacogenomics

1 reference

based on heuristic

inferred from title

Helicobacter pylori infectious disease

1 reference

based on heuristic

inferred from title

author name string

Takahisa Furuta

1

1 reference

Europe PubMed Central

3 August 2017

Mitsushige Sugimoto

2

1 reference

Europe PubMed Central

3 August 2017

Naohito Shirai

3

1 reference

Europe PubMed Central

3 August 2017

Takashi Ishizaki

4

1 reference

Europe PubMed Central

3 August 2017

publication date

1 September 2007

1 reference

Europe PubMed Central

3 August 2017

Pharmacogenomics

1 reference

Europe PubMed Central

3 August 2017

8

1 reference

Europe PubMed Central

3 August 2017

1199-1210

1 reference

Europe PubMed Central

3 August 2017

9

1 reference

Europe PubMed Central

3 August 2017

Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Rabeprazole: an update of its use in acid-related disorders

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Symptomatic gastroesophageal reflux: incidence and precipitating factors

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Helicobacter pylori infection and the development of gastric cancer

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

The life and death of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

The role of internal urease in acid resistance of Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.9.1199

21 January 2018

Identifiers

10.2217/14622416.8.9.1199

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34583603&oldid=1962309241"